Interpace Diagnostics Group Inc. (NASDAQ:IDXG) is Attracting Smart Money

0
47

 

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Interpace Diagnostics Group Inc. (NASDAQ:IDXG) reported that Armistice Capital has picked up 965,784 of common stock as of 2017-06-23.

The acquisition brings the aggregate amount owned by Armistice Capital to a total of 965,784 representing a 4.99% stake in the company.

For those not familiar with the company, Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

A glance at Interpace Diagnostics Group Inc. (NASDAQ:IDXG)’s key stats reveals a current market capitalization of $15.52 Million based on $18.69 Million shares outstanding and a price at last close of $0.860 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2014-11-25, Miao picked up 21,400 at a purchase price of $1.65. This brings their total holding to 63,899 as of the date of the filing.

On the sell side, the most recent transaction saw Melillo unload 1,748 shares at a sale price of $0.77. This brings their total holding to 130,173  .

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Interpace Diagnostics Group Inc. (NASDAQ:IDXG) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.